Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10753634rdf:typepubmed:Citationlld:pubmed
pubmed-article:10753634lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:10753634lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10753634lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10753634lifeskim:mentionsumls-concept:C0893816lld:lifeskim
pubmed-article:10753634pubmed:issue2lld:pubmed
pubmed-article:10753634pubmed:dateCreated2000-5-8lld:pubmed
pubmed-article:10753634pubmed:abstractTextBorato-1,2-diaminocyclohexane platinum (II) (BDP) was synthesized and compared to cisplatin (cisPt) as a potential anti-tumor drug. BDP and cisPt (0.2-20 microM) dose-dependently inhibited DNA synthesis in L1210 murine leukemia cells, DU-145 prostate cancer cells, A549 lung carcinoma cells, and MCF-7 breast cancer cells, as judged by measuring [(3)H]-thymidine incorporation. BDP and cisPt induced killing of L1210 murine cells by 97 and 78%, respectively. The LD(50) was 35 and 14 mg/kg for BDP and cisPt, respectively. Interestingly, while cisPt (at optimal dose) induced a 100% increase in life span (ILS) of BDF1 mice bearing L1210 tumor cells, BDP (at optimal dose) induced a 200% increase in ILS in the same tumor model. In conclusion, BDP is a novel platinum derivative compound that appears more effective in increasing the ILS than cisplatin against the leukemia tumor mouse model.lld:pubmed
pubmed-article:10753634pubmed:languageenglld:pubmed
pubmed-article:10753634pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10753634pubmed:citationSubsetIMlld:pubmed
pubmed-article:10753634pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10753634pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10753634pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10753634pubmed:statusMEDLINElld:pubmed
pubmed-article:10753634pubmed:monthAprlld:pubmed
pubmed-article:10753634pubmed:issn0006-291Xlld:pubmed
pubmed-article:10753634pubmed:authorpubmed-author:StewartDDlld:pubmed
pubmed-article:10753634pubmed:authorpubmed-author:HowardJJlld:pubmed
pubmed-article:10753634pubmed:authorpubmed-author:KhanAAlld:pubmed
pubmed-article:10753634pubmed:authorpubmed-author:AnwarSSlld:pubmed
pubmed-article:10753634pubmed:authorpubmed-author:DibasAAlld:pubmed
pubmed-article:10753634pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:10753634pubmed:issnTypePrintlld:pubmed
pubmed-article:10753634pubmed:day13lld:pubmed
pubmed-article:10753634pubmed:volume270lld:pubmed
pubmed-article:10753634pubmed:ownerNLMlld:pubmed
pubmed-article:10753634pubmed:authorsCompleteYlld:pubmed
pubmed-article:10753634pubmed:pagination383-6lld:pubmed
pubmed-article:10753634pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:meshHeadingpubmed-meshheading:10753634...lld:pubmed
pubmed-article:10753634pubmed:year2000lld:pubmed
pubmed-article:10753634pubmed:articleTitleBorato-1,2-diaminocyclohexane platinum (II), a novel anti-tumor drug.lld:pubmed
pubmed-article:10753634pubmed:affiliationMary Kay Ash Institute for Cancer Research, St. Paul Medical Center, Dallas, Texas 75235, USA.lld:pubmed
pubmed-article:10753634pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10753634pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed